COVID-19 Biorepository

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

201 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-04-15

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Establish a COVID-19 biorepository to aid in developing our knowledge of the disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Caris Biorepository Research Protocol

NCT01499394

Cancer Early Detection of Cancer Minimal Residual Disease

RECRUITING

The Biorepository for Scripps Health

NCT01006239

Cancer

ACTIVE_NOT_RECRUITING

Efficacy and Safety of COVID-19 Vaccine in Cancer Patients

NCT04865133

COVID-19 Infection Malignant Solid Neoplasm

COMPLETED

Louisville Cooperative Tissue Biorepository

NCT02021916

Normal and Abnormal Tissue

COMPLETED

Vincere Biobank Research Protocol

NCT05954299

Cancer

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

While SARS-CoV-2 has some similarities to the SARS-CoV pathogen that led to an epidemic in 2002 and 2003, there is much about the epidemiology, pathogenesis, clinical presentation, diagnosis, and treatment of the novel virus that remains unknown.3 Additional research is needed to explore the nature of the virus, its spectrum of disease, and potential therapies to combat its spread. The aim of this project will be to establish a biorepository of blood samples from patients infected with SARS-CoV-2 that can then be used by investigators to expand our understanding of COVID-19 and its treatment and, in turn, improve patient outcomes.

The COVID-19 biorepository will accomplish the following specific aims:

1. Establish a collection of biospecimens from patients with COVID-19.
2. Establish a link between biospecimens and longitudinal individual patient data, which will be collected and stored in RedCap.
3. Provide biospecimens and unique patient data to researchers investigating COVID-19. Separate IRB approval will be needed for these studies.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Covid-19 SARS-CoV 2 Coronavirus COVID

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The participant is a patient at TUKHS or has agreed to participate in a study approved by the KUMC Human Research Protection Program (HRPP).
* The participant has a diagnosis of COVID-19 confirmed by COVID-19 PCR.
* Patient is 18 years of age or older.

Exclusion Criteria

* Participant declines to participate (living patients only)
* Participant or healthcare surrogate is unable to provide informed consent (living patients only)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No